SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness

Autor:in

Nguyen, Chi Huu; Gluexam, Tobias; Schlerka, Angela; Bauer, Katharina; Grandits, Alexander Michael; Hackl, Hubert; Dovey, Oliver; Zoechbauer-Mueller, Sabine; Cooper, Jonathan L.; Vassiliou, George S.; Stoiber, Dagmar; Wieser, R.; heller, gerwin

Abstrakt

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients' outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is still an issue. Here, we used a robust likelihood-based survival modeling approach and publicly available gene expression data to identify a minimal number of genes whose combined expression values were prognostic of overall survival. The resulting gene expression signature (4-GES) consisted of 4 genes (SOCS2, IL2RA, NPDC1, PHGDH), predicted patient survival as an independent prognostic parameter in several cohorts of AML patients (total, 1272 patients), and further refined prognostication based on the European Leukemia Net classification. An oncogenic role of the top scoring gene in this signature, SOCS2, was investigated using MLL-AF9 and Flt3-ITD/NPM1c driven mouse models of AML. SOCS2 promoted leukemogenesis as well as the abundance, quiescence, and activity of AML stem cells. Overall, the 4-GES represents a highly discriminating prognostic parameter in AML, whose clinical applicability is greatly enhanced by its small number of genes. The newly established role of SOCS2 in leukemia aggressiveness and stemness raises the possibility that the signature might even be exploitable therapeutically.

Dokumententyp

Originalarbeit

Open Access Type

Gold

DOI

10.1038/s41598-019-45579-0

PubMed ID

MEDLINE:31235852